The coprimary endpoints were the proportion of zasocitinib-treated patients achieving static Physician Global Assessment (sPGA) of clear (0) or almost clear (1) and Psoriasis Area and Severity Index ...
Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...
Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...
A real-world analysis reveals that tildrakizumab is highly effective and safe in patients with moderate-to-severe plaque ...
Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, ...
Everyday Health on MSN
What to know about tattoos if you have psoriasis
A tattoo can trigger a psoriasis flare. These tips will help you reduce that risk and keep your tattoos looking good.
Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis. We conducted a phase 3, double-blind, randomized, ...
Please provide your email address to receive an email when new articles are posted on . There is an unmet need for a safe and effective oral treatment for moderate to severe plaque psoriasis. In two ...
Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...
"Achieving complete skin clearance is a key treatment target for all patients with plaque psoriasis, as it prevents the cumulative burden of disease and potentially progression to PsA," said Richard B ...
Johnson & Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) on Wednesday released new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies of icotrokinra compared to deucravacitinib ...
Sept 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's (BMY.N), opens new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback